(Q43254054)

17 November 2017

title

Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma (English)

1 reference

17 November 2017

1 reference

Peter Moosmann

1

1 reference

17 November 2017

Marc Heizmann

2

1 reference

17 November 2017

Nina Kotrubczik

3

1 reference

17 November 2017

Martin Wernli

4

1 reference

17 November 2017

Mario Bargetzi

5

1 reference

17 November 2017

publication date

1 January 2010

1 reference

17 November 2017

1 reference

17 November 2017

volume

51

1 reference

17 November 2017

issue

1

1 reference

17 November 2017

page(s)

149-152

1 reference

Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents.

17 November 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275602

Bendamustine: rebirth of an old drug

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275602

Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275602

Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275602

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275602

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275602

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275602

Bortezomib for the treatment of mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275602

Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275602

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275602

Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F10428190903275602

10.3109/10428190903275602

21 January 2018

Identifiers

DOI

1 reference

17 November 2017

1 reference